ACAAI 2025 Conference Preview: 5 Trials to Watch Out For

With the 2025 American College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting now a day away, kicking off on November 6, 2025, in sunny Orlando, Florida, it is time to review what late-breaking presentations and expert perspectives to expect during the meeting (and what to look forward to!).

The HCPLive editorial team will be on-site during the meeting, covering late-breaking presentations, sessions, and interviewing 10+ key experts in the allergy field. Coverage will span across numerous specialties, from peanut allergy and hereditary angioedema to more skin-related diseases like atopic dermatitis and chronic spontaneous urticaria.

To stay up to date with everything going on during the meeting, you can keep up with our comprehensive ACAAI coverage here.

Ahead of the meeting, we previewed a select handful of slated expert interviews and 5 late breakers you will not want to miss.

Brief Preview of Expert Interviews:

Raj Chovatiya, MD, PhD, MSCI, FAAD, from Northwestern Medicine, who will discuss the target OX40/OX40L in allergy and immunology care.

Jonathan A Bernstein, MD, from the University of Cincinnati, who will discuss phase 2 findings on povorcitinib for adult chronic spontaneous urticaria.

Marcus S. Shaker, MD, from Dartmouth Health, who will discuss when to test for anaphylaxis.

Gary L. Gross, MD, FACAAI, from Jersey Shore University Medical Center, who will discuss the allergy coding update.

Vinay Mehta, MD, from Allergy & Asthma Associates of Southern California, who will discuss the effectiveness of lebrikizumab for atopic dermatitis among patients with skin of color.

Other featured experts will include Raquel Durban, RD, LD/N (Carolina Asthma & Allergy Center), Raffi Tachdjian, MD, MPH (UCLA Health), Adnan Al Ali, MD, PhD (United Arab Emirates University), Geoff Harris, PhD (Dermavant), Amber Luong, MD, PhD (UT Health Houston), Patricia Stewart, MD (University of Pikeville), Jason A. Trubian, MD, MBBS (Austin Health),Joseph K. Han, MD, FARS, FAAOA (Old Dominion University), Vinay Mehta, MD (Allergy & Asthma Associates of Southern California), among others.

Trials to Watch For at ACAAI

1.Benralizumab For Patients with Hypereosinophilic Syndrome: A Randomized Double-Blind Placebo-Controlled Phase 3 Trial (NATRON)

Presentation Time: Saturday, November 8, 2025, at 5:23 (Room: W230CD)

Presenter: Princess Ogbogu, MD, FACAAI

Background Info: The phase 3 NATRON trial evaluated benralizumab, an anti–IL-5 receptor α monoclonal antibody that depletes eosinophils, versus placebo in patients with FIP1L1-PDGFRA–negative, steroid-responsive hypereosinophilic syndrome. The primary endpoint was time to first HES worsening/flare, with secondary endpoints assessing flare rates, hematologic relapse, and fatigue changes.1

2. Long-Term Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: EPOPEX End of Study Results

Presentation time: Saturday, November 8, 2025, at 4:43 pm (Room: W231)

Presenter: Matthew Greenhawt, MD, MBA, MSc, FACAAI

Background Info: The phase 3 EPITOPE open-label extension (OLE) study builds on the pivotal EPITOPE trial, which demonstrated that epicutaneous immunotherapy with the VIASKIN peanut patch (VP250) significantly improved peanut tolerance in allergic toddlers aged 1–3 years. In the OLE, eligible participants from the original 12-month, double-blind, placebo-controlled trial continued VP250 treatment for up to 3 years, undergoing annual food challenges and safety assessments to evaluate the long-term efficacy and safety of this therapy in young children with peanut allergy.2

3. Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria: Phase 2 Results

Presentation Time: Saturday, November 8, 2025, at 5:43 pm (Room: W230CD)

Presenter: Jonathan A. Bernstein, MD, FACAAI

Background Info: The phase 2 trial of povorcitinib is a double-blind, randomized, placebo-controlled, dose-ranging study designed to evaluate the efficacy and safety of povorcitinib in adults with CSU inadequately controlled with standard-of-care treatments. Sponsored by Incyte Corporation, the study enrolled 136 participants and assessed multiple doses of povorcitinib versus placebo, with the goal of determining its ability to reduce hives, angioedema, and pruritus while maintaining a favorable safety profile.3

4. Rezpegaldesleukin Novel Treg-Inducing therapy Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial

Presentation Time: Saturday, November 8, 2025, at 5:33 pm (Room: W231)

Presenter: Jonathan Corren, MD, FACAAI

Background Info: The REZOLVE-AD Phase 2b study is evaluating rezpegaldesleukin, an IL-2 pathway agonist that stimulates regulatory T cells, in moderate-to-severe atopic dermatitis patients naive to biologics or JAK inhibitors. Rezpegaldesleukin is a self-administered injection and has FDA Fast Track designation for atopic dermatitis and severe alopecia areata. The study’s primary endpoint is improvement in EASI scores, with secondary endpoints including investigator global assessment, itch reduction, biomarkers, and asthma control.4

5. Sebetralstat for On-demand Treatment of Hereditary Angioedema in Pediatric (2-11y) Patients: Interim Results from KONFIDENT-KID

Presentation Time: Saturday, November 8, 2025, at 5:13 (Room: W230CD)

Presenter: Adil Adatia, MD

Background Info: KTERLY (sebetralstat) is a novel oral plasma kallikrein inhibitor approved for on-demand treatment of HAE in patients 12 years and older, providing an efficacious alternative to injectable therapies. The KONFIDENT-KID study evaluates the safety and efficacy of EKTERLY in children aged 2–11 years, aiming to expand treatment options for pediatric patients with HAE.5

References

1. Akuthota P, Klion AD, Ogbogu P, et al. The Phase 3 Natron Study Evaluating Benralizumab in Patients with Hypereosinophilic Syndrome: Study Design and Patient Characteristics. Blood. 2023;142(Supplement 1):1172-1172. doi:https://doi.org/10.1182/blood-2023-179404

2. Greenhawt M, Albright D, Anvari S, et al. Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE. J Allergy Clin Immunol Pract. 2025;13(5):1176-1187.e7. doi:10.1016/j.jaip.2025.02.004

3. Clinicaltrials.gov. Published 2025. Accessed November 5, 2025. https://www.clinicaltrials.gov/study/NCT05936567

4. Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting | Nektar Therapeutics. Nektar Therapeutics. Published 2025. Accessed November 5, 2025. https://ir.nektar.com/news-releases/news-release-details/data-rezolve-ad-phase-2b-study-rezpegaldesleukin-accepted-late

5. KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting | KalVista Pharmaceuticals. KalVista Pharmaceuticals. Published 2025. Accessed November 5, 2025. https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-present-new-ekterlyr-sebetralstat-0/